• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CareDx (CDNA) Following Its Rally, Is The Transplant Testing Story Still Fully Valued

    Simply Wall St·10/20/2026 10:29:13
    Listen to the news

    CareDx (CDNA) drew fresh attention after a recent share price move that left the stock up 25% over the past month and about 74% over the past 3 months.

    The recent move in CareDx comes on top of strong momentum, with a 30 day share price return of about 25% and a 90 day share price return of roughly 74% feeding into a year to date share price gain above 250% and a 1 year total shareholder return above 340%. The 3 year total shareholder return is very large at close to 12x despite a slightly negative 5 year total shareholder return. This suggests sentiment has swung sharply as investors reassess both the company’s growth potential and its risk profile around the current US$67.08 share price.

    Scan how CareDx’s surge compares with other healthcare stocks showing strong recent momentum across our hand picked 33 healthcare AI stocks.

    After such a sharp move in CareDx, the key focus now is the trade-off between chasing the momentum and protecting downside. Does the current valuation still offer a fair balance of risk and reward for new capital?

    Most Popular Narrative: 14% Overvalued

    CareDx is trading at $67.08 against a widely followed fair value estimate of about $58.83, which frames the current rally as stretching above that narrative benchmark even as the story leans heavily on growth in transplant testing and digital health.

    The steady double-digit growth in testing volumes, particularly with the expansion of surveillance protocols for kidney, heart, and lung transplants, suggests ongoing market penetration and growing demand for CareDx's core testing services, reflecting the global rise in organ transplants and chronic disease, which is likely to drive future revenue and topline growth.

    See why 6 investors see CareDx as 14% overvalued.

    Result: Fair Value of $58.83 (OVERVALUED)

    Still, the narrative around CareDx could shift quickly if Medicare reimbursement or bundled payment policies tighten more than expected, and if execution on digital health and Naveris underwhelms raised expectations.

    Find out about the key risks to this CareDx narrative.

    Another View: SWS DCF Puts CareDx In A Different Bucket

    The popular fair value story says CareDx looks about 14% overvalued at $67.08 against a $58.83 estimate. A second lens tells a very different story. The SWS DCF model puts future cash flows at roughly $100.03 per share, which makes the current quote look materially undervalued instead of stretched. Which narrative do you trust more: the near term sentiment around earnings multiples, or the longer term cash flow math?

    Look into how the SWS DCF model arrives at its fair value.

    CDNA Discounted Cash Flow as at Oct 2026
    CDNA Discounted Cash Flow as at Oct 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CareDx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 35 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Sentiment on CareDx is clearly charged in both directions, with both optimism around the story and pointed concerns. Act quickly, review the data yourself, and pressure test the trade off between opportunity and risk by weighing its 2 key rewards and 3 important warning signs

    Looking for more investment ideas beyond CareDx?

    If CareDx has sharpened your conviction, do not stop here. Broaden your watchlist with a few focused stock ideas that match different risk and return preferences.